Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. PPD is one of the most common medical complications during and after pregnancy. It is important to take care of yourself because experiencing symptoms of PPD may have consequences. In clinical studies, moms who took ZULRESSO experienced a greater improvement in symptoms of postpartum depression vs placebo in 2.5 days. Symptoms were measured at the beginning of treatment using a standard depression scale and again at the end of treatment. Zulresso is the first-ever FDA-approved treatment for postpartum depression.